The steep rise in the Automated Compounding Device (Oncology) Market can be ascribed to the emergent need to reduce medicinal errors and a growing preference of cancer patients for personalized medicines and chemotherapy.
LAS VEGAS, July 15, 2021 /PRNewswire/ -- DelveInsight's Automated Compounding Device (Oncology) Market Insights and Forecast report provides the current and forecast Automated Compounding Device (Oncology) market, individual market shares of the devices, upcoming innovation in the devices, challenges, and drivers and comprises market trends and key competitors in the Automated Compounding Device (Oncology) market.
Some of the key takeaways from the Automated Compounding Device (Oncology) Market report:
- The United States accounts for the majority of the Automated Compounding Devices (Oncology) market size in 2021 in the 7MM.
- France accounts for the highest ACD (Oncology) market size in the EU5 countries followed by Germany, the UK, Italy, and Spain.
- As per DelveInsight's Automated Compounding Devices (Oncology) market analysis, the majority of the end-users for ACD (Oncology) devices constitute hospitals and chemotherapy centers.
- Key companies actively operating in the Automated Compounding Devices (Oncology) market include Comecer, Arxium, Loccioni, ICU Medical, Omnicell, Inc, Baxter Healthcare Corporation, Grifols International, S.A., Equashield, B. Braun Medical Inc., Weibond Technologies, among others.
- Key factors expediting the growth of the Automated Compounding Devices (Oncology) market size include an increase in the adoption of chemotherapy and personalized medicine, reduced exposure to cytotoxic compounds, better efficiency, and accuracy proffered by the devices, and a comparatively reduced risk of contamination.
- The Automated Compounding Devices (Oncology) market size growth is expected to face backlash owing to the high installation cost of these devices and a lack of skilled resources.
- On 6 December 2018, Arxium had launched its cGMP RIVA IV, a fully automated compounding system for hospitals and outsourcing pharmacies.
- Fagron acquired JCB Laboratories in the year 2015 to reshape the U.S. Sterile Compounding Industry and it had announced in 2019 about opening one of the largest 503B human drug outsourcing facilities in the U.S.
- On 23 January 2018, an array of hospitals had adopted Omnicell's IV compounding technology across North Carolina, for the purpose of enhancing safety, providing improved therapy, reduction in costs, and facilitating compliance in the IV room.
Know which MedTech player is expected to be the growth king @ Automated Compounding Device (Oncology) Market Insights and Forecast
Automated Compounding Device (Oncology): Overview
Automated Compounding Device (Oncology) are the devices that help in aseptically transfer one or more sterile component solutions to a sterile final container for patient preparation, thus, minimizing the use of syringes for the same purpose. The devices are known for offering better accuracy of ingredient delivery along with reducing the preparation time as well as limiting the injuries on the patients.
Discover more about the device, its components, and working mechanism @ Automated Compounding Device (Oncology) Devices
Automated Compounding Device (Oncology) Devices Market
The Automated Compounding Device (Oncology) market is witnessing a lot of shuffling in the market with several ongoing trials investigating the safety and efficacy of the devices, collaborations and deals happening in the space, and a gamut of MedTech players setting their food in the market. As per DelveInsight's ACD (Oncology) market analysis, the market is segmented by technology, product type, and end-user. The devices based on product type are further segmented into Macro, Micro, and Macro/Microdevices. The devices based on technology are divided into Gravimetric and Volumetric devices. The end-user Automated Compounding Device (Oncology) Devices market is majorly dominated by hospitals and chemotherapy centers.
The market of the Automated Compounding Devices (Oncology) is driven due to the reduction of the cost incurred at the hospitals per dose and elimination of contamination which is required during compounding solutions. Also, the growing need required for reducing medicinal errors are factors responsible for the growth of the Automated Compounding Devices (Oncology) market size at a high CAGR during the forecast period.
Automated Compounding Device (Oncology) Devices Portfolio
Device | Company | Technology |
APEX Compounding System | B. Braun Medical Inc. | Gravimetric/ Volumetric |
Equashield Pro | Equashield | Gravimetric |
KIRO Oncology | Grifols International, S.A | Gravimetric |
IV pharmacy compounding automation | Omnicell | Gravimetric |
Diana Compounding Workflow System | ICU Medic | Gravimetric |
RIVA IV compounding system | Arxium | Volumetric |
Pharmoduct | Comecer | Gravimetric/ Volumetric |
WEINAS PD-160 series | Weibond Technology | Gravimetric |
Get in touch to know which device is expected to enter the market first @ Automated Compounding Device (Oncology) Pipeline Analysis and Competitive Assessment
Key MedTech Players in the Automated Compounding Device (Oncology) Market
- Comecer
- Arxium
- Loccioni
- ICU Medical
- Omnicell Inc
- Baxter Healthcare Corporation
- Grifols International
- S.A., Equashield
- B. Braun Medical Inc.
Automated Compounding Device (Oncology) Devices Market Dynamics
The Automated Compounding Device (Oncology) Devices market size growth is expected to pick up its pace attributable to factors such as rising adoption rate for accurate dosage units for chemotherapy drugs, an inclination towards personalized medicines, continuous technological advancements, less exposure to cytotoxic compounds to personnel, low errors during dosage preparations, minimal risks, and contamination rate. However, a high installation cost of the device appears to be challenging in the smooth adoption of the devices. Further, the devices are categorized under class II medical devices, which asks the sponsor to comply with the Quality Management System (QMS) that meets FDA Quality System Regulation (QSR) making their regulatory approval quite stringent.
Know more about which MedTech player is set to emerge as the trendsetter @ Automated Compounding Device (Oncology) Market Key Companies and Pipeline Therapies
Table of Content
1 | Key Insights |
2 | Executive Summary of Automated Compounding Devices (Oncology) |
3 | Automated Compounding Devices (Oncology): Background and Overview |
4 | Automated Compounding Device (Oncology): Regulatory Approval |
5 | Automated Compounding Devices (Oncology): Reimbursement Scenario |
6 | Automated Compounding Devices (Oncology): Competitive Analysis of Listed Products |
7 | Automated Compounding Devices: Market Analysis in 7MM |
8 | Country-Wise Market size of Automated Compounding Devices in 7MM |
9 | KOL's Views |
10 | Automated Compounding Devices (Oncology) Market Drivers |
11 | Automated Compounding Devices (Oncology) Market Barriers |
12 | Unmet Needs in the Automated Compounding Devices (Oncology) Market |
13 | PEST Analysis |
14 | Conclusion and Future Perspectives |
15 | Appendix |
16 | DelveInsight Capabilities |
17 | Disclaimer |
18 | About DelveInsight |
Visit to know more about the report offerings @ Automated Compounding Device (Oncology) Market Insights and Forecast
Scope of the Report
Coverage: 7MM
Study Period: 2018-26
Automated Compounding Device (Oncology) Market Segmentation
- By Technology-
- Gravimetric compounding system
- Volumetric compounding system
- By Product Type-
- Macro automated compounding systems
- Micro automated compounding systems
- Macro/micro automated compounding systems
- By End-User
- Hospitals
- Chemotherapy centers
Automated Compounding Device (Oncology) Key Companies: Comecer, Arxium, Loccioni, ICU Medical, Omnicell, Inc, Baxter Healthcare Corporation, Grifols International, S.A., Equashield, B. Braun Medical Inc., Weibond Technologies, and others.
Request for sample report for penetrated insights @ Automated Compounding Device (Oncology) Market Landscape and Future Trends
DelveInsight's Methodology
The report provides valuable insight for clients venturing into the Automated Compounding Device (Oncology) market and acts as the source of guidance for taking strategic business decisions in the field of Automated Compounding Device (Oncology) by providing a descriptive overview of Automated Compounding Device (Oncology), various applications of Automated Compounding Device (Oncology) and their types including detailed chapters for marketed products and emerging therapies. Along with this, the report has a detailed review of the market containing historical and forecasted market size in 7MM, by understanding the trends shaping and driving the global Automated Compounding Device (Oncology).
This report has been prepared by DelveInsight's analysts after a thorough secondary and primary research into the Automated Compounding Device (Oncology) market domain. Analysis and estimations are done by taking into consideration the share of topmost companies and industry expert viewpoints of Automated Compounding Device (Oncology) of 7MM countries.
Related Reports
3d Cardiac Mapping System Market
DelveInsight's '3D Cardiac Mapping System Market Insights, Competitive Landscape and Market Forecast-2026' report offers a complete analysis of market space, pipeline therapies and key MedTech players including Biosense Webster, Inc. (Jhonson & Jhonson), Boston Scientific Corporation, Inc., Abbott, Kardium, Medtronic, Catheter Robotics, Lepu Medical, EP Solutions SA, among others.
Advanced Wound Care Market
DelveInsight's 'Advanced Wound Care (AWC) Market Insights, Competitive Landscape and Market Forecast-2026' report offers a complete analysis of market space, pipeline therapies and key MedTech players including Smith & Nephew plc, Acelity L.P. Inc., Mölnlycke Health Care AB, Convatecgroup, Coloplast, Paul Hartmann AG, Medtronic plc., 3M Company, Integra LifeSciences Holding Corporation, Lohmann & Rauscher International GmbH & Co. KG, and others.
Adult Spinal Deformity Market
DelveInsight's 'Adult Spinal Deformity Market Insights, Competitive Landscape and Market Forecast - 2026' report offers a complete analysis of market space, pipeline therapies and key MedTech players including NuVasive, Inc., Stryker, B. Braun Melsungen AG, Zimmer Biomet, Globus Medical, Orthofix Medical Inc., Abbott, RTI Surgical, Boston Scientific Corporation, SeaSpine, among others.
Angio Suites Market
DelveInsight's 'Angio Suites Market Insights, Competitive Landscape and Market Forecast-2026' report offers a complete analysis of market space, pipeline therapies and key MedTech players including GE Healthcare, Philips Healthcare, Canon Medical Systems Corp., Shimadzu Corp., Siemens Healthcare GmbH, Koninklijke Philips N.V., and others.
Apheresis Market
DelveInsight's 'Apheresis - Market Insights, Competitive Landscape and Market Forecast-2026' report offers a complete analysis of market space, pipeline therapies and key MedTech players including Terumo BCT, Inc., Fresenius SE & Co. KGaA, Haemonetics Corporation, Asahi Kasei Medical Co. Ltd., B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, Kaneka Corporation, Kawasumi Laboratories, Inc., Nikkiso Co., Ltd., and several others.
Artificial Disc Market
DelveInsight's 'Artificial Disc Market Insights, Competitive Landscape and Market Forecast - 2026' report offers a complete analysis of market space, pipeline therapies and key MedTech players including Globus Medical, Zimmer Biomet, B. Braun Melsungen, Centinel Spine, LLC, Medtronic Plc, AxioMed LLC, NuVasive Inc, Orthofix Medical Inc, K2M, Inc, RTI Surgical Holdings, Inc, Synergy Disc Replacement Inc., and others.
Related Posts
Neurovascular Thrombectomy Devices Market
Wearable Devices: Pros and Cons
Diabetic Macular Edema Therapy Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Manage portfolio, expand business, audit market with DelveInsight's Consulting Solutions and Services.
Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
